Top 5 Losers In Healthcare Sector (NXTC, SNDX, COCP…)

(RTTNews) - The following are some of the healthcare stocks that posted the biggest percentage decline on Wednesday.

1. Cocrystal Pharma Inc. (COCP)

Cocrystal Pharma is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics.

Lost 14.44% to close Wednesday's (Oct.9) trading at $1.54.

News: No news

Clinical Trials & Near-term Catalysts:

-- A phase IIa study of CC-31244 for the treatment of hepatitis C as part of a cocktail for ultra-short therapy of 4 to 6 weeks is ongoing in Hong Kong SAR, China. Interim safety results for the Hong Kong Phase 2a study are expected in Q4 2019, with topline results anticipated in Q1 2020. -- Preclinical IND-enabling studies of CC-42344, the Company's molecule for the treatment of influenza A, are underway. The preclinical IND-enabling studies are expected to be completed in Q1 2020.

2. Artelo Biosciences Inc. (ARTL)

Artelo is a clinical-stage biopharmaceutical company with a portfolio of novel therapeutic candidates targeting the endocannabinoid system.

Lost 13.27% to close Wednesday's trading at $1.83.

News: No news

Clinical Trials:

-- The lead drug candidate is ART27.13 for the treatment of cancer-related anorexia and weight loss. In five Phase I clinical studies including over 200 subjects, ART27.13 demonstrated a statistically significant and dose-proportional increase in body weight, according to the Company.

3. Syndax Pharmaceuticals Inc. (SNDX)

Syndax Pharma is a late-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications.

Lost 11.85% to close Wednesday's trading at $5.43.

News: No news

Pipeline:

The Company's lead product candidate is Entinostat, which is being developed for advanced hormone receptor-positive breast cancer and for multiple solid tumors.

The most advanced clinical trial is E2112, a phase III registration trial of Entinostat plus exemestane in HR+, HER2- breast cancer, which has passed its fourth interim overall survival analysis. The next preplanned analysis is expected in the fourth quarter of this year.

Also in the pipeline are SNDX-5613 and SNDX-6352.

-- SNDX-5613 is under a phase 1/2 open-label trial in adults with relapsed/refractory (R/R) acute leukemia, dubbed AUGMENT. Initial data from this study is expected in 2020. -- SNDX-6352 is under a phase I study in subjects with chronic graft versus host disease, with initial results expected in the second half of 2020.

3. INmune Bio Inc. (INMB)

INmune Bio is a clinical-stage biotechnology company developing new immunotherapies for cancer and Alzheimer's.

Lost 13.19% to close Wednesday's trading at $4.08.

News: No news

Pipeline:

The Company has four drug development programs: two that are designed to treat cancer, INKmune and INB03.

-- Preliminary data from the Phase 1 trial of INB03 in patients with advanced cancer were reported recently. Final results from the trial are expected later this year, followed by a phase II study. -- Patient enrollment in a phase I trial of INKmune, the Company's NK cell therapy focused on eliminating residual disease after cancer therapy, is expected in the second half of 2019. -- Patient enrollment in a phase I trial of XPro1595 for the treatment of Alzheimer's disease is expected in the second half of 2019. -- NeuLiv development program for the treatment of nonalcoholic steatohepatitis.

4. Provention Bio Inc. (PRVB)

Provention Bio is a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases.

Lost 10.60% to close Wednesday's trading at $5.99.

News: No news

Clinical Trials & Near-term Catalysts:

-- A phase III trial of PRV-031 (teplizumab) in patients with recent-onset type 1 diabetes, dubbed PROTECT, is underway. Enrollment in this study is expected to be completed in Q4 2020, with data anticipated in 2022. -- Expect to file IND for PRV-101 vaccine to prevent Type 1 Diabetes and initiate Phase 1 trial in 2020. -- A phase 1b/2a study of PRV-3279 in lupus, dubbed PREVAIL, is underway, with topline results from the Phase 1b part anticipated in Q1 2020. -- A Phase 2b trial of PRV-015 in Celiac disease is planned for initiation in the first half of 2020. -- A phase 2a study of PRV-6527 in Crohn's disease, dubbed PRINCE, is ongoing, with topline results expected in Q4, 2019.

5. NextCure Inc. (NXTC)

NextCure Inc is a clinical-stage biopharmaceutical company developing next-generation immunomedicines for cancer and other immune-related diseases by restoring normal immune function.

Lost 10.39% to close Wednesday's trading at $25.54.

News: No news

Near-term Catalysts:

-- A Phase 1/2 clinical trial to evaluate NC318 as a monotherapy in patients with advanced or metastatic solid tumors is enrolling patients. The Phase 1 portion of the trial is designed to assess the safety and tolerability of NC318, with clinical data from this part expected to be presented on November 9, 2019. -- An investigational new drug application for the second cancer drug candidate, NC410, to advance the compound in phase I testing is expected to be submitted to the FDA in the first quarter of 2020.